{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:15Z","timestamp":1787682435641,"version":"build-2784847793"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.msard.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:32:54Z","timestamp":1560511974000},"page":"14-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Optic neuritis, encephalitis and leptomeningeal enhancement in a patient with anti-MOG antibodies: A case study"],"prefix":"10.1016","volume":"34","author":[{"given":"Nichola","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breton","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2019.06.010_bib0001","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2019.06.010_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2019.06.010_bib0002","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2019.06.010_bib0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.msard.2019.06.010_bib0003","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.msard.2018.07.028","article-title":"A case of anti-MOG antibody-positive unilaterally dominant meningoencephalitis followed by longitudinally extensive transverse myelitis","volume":"25","author":"Sugimoto","year":"2018","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819302536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819302536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:54Z","timestamp":1761900354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819302536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":5,"alternative-id":["S2211034819302536"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.06.010","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optic neuritis, encephalitis and leptomeningeal enhancement in a patient with anti-MOG antibodies: A case study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}